Tobramycin (nebulised) – Pseudomonas aeruginosa infection in patients with Cystic Fibrosis

Drug Name (Brand)	Tobramycin (nebulised) *(Tobi®, Bramitob®)*
Indication	Pseudomonas aeruginosa infection in patients with Cystic Fibrosis
Traffic Light Classification	Red
NICE TA (plus link)
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. March 2013: Shared care agreement reviewed to include Bramitob. Supported by the TAG and the D&TCG. Use of shared care agreement to be continued during transition of CF services to the NHS England Specialised Commissioning Group (SCG) i.e. as Amber (option for GP prescribing under an approved shared care prescribing agreement) during 2013 as necessary. Available via http://nww.knowledgeanglia.nhs.uk/tag/shared_care/tobramycin_nebuliser_sltn.pdf April 2013: NHS England SCG took over commissioning responsibility for this treatment. March 2014: Shared Care Agreement reviewed and use extended until March 2015. Supported by the TAG and D&TCG. March 2015: The TAG was asked to review classification from Amber (Option for GP prescribing under an approved Shared Care Agreement) to Red since confirmation had been received that all local patients have been repatriated. The shared care agreement could therefore be revoked. The TAG confirmed that classification of Red (Hospital/Specialist only) should be recommended for Tobramycin Nebuliser Solution for chronic pulmonary infection in CF. March 2015: The Norfolk & Waveney CCGs’ D&TCG noted and supported the TAG’s recommendation to re-classify Tobramycin Nebuliser Solution for use in patients with cystic fibrosis to Red (Hospital/Specialist only). November 2017: The TAG acknowledged NICE NG 78 (October 2017) – Cystic fibrosis: diagnosis and management
Date of TAG recommendation / ratification		3/1/2015	Review Date	1/4/2027